Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Imprimis Pharmaceuticals, Inc. (IMMY)


Recently stock market analysts have updated their consensus ratings on shares of Imprimis Pharmaceuticals, Inc. (IMMY).

Most recent broker ratings

07/23/2015 – Sterne Agee began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.

03/10/2015 – Imprimis Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 8.4 price target on the stock.

12/18/2014 – CRT Capital began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock.

12/16/2014 – Craig-Hallum began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 12 price target on the stock.

Imprimis Pharmaceuticals, Inc. has a 50 day moving average of 3.79 and a 200 day moving average of 3.85. The stock’s market capitalization is 40.59M, it has a 52-week low of 3.00 and a 52-week high of 8.79.

The share price of the company (IMMY) was down -5.23% during the last trading session, with a high of 3.34 and the volume of Imprimis Pharmaceuticals, Inc. shares traded was 66320.

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.